Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Pertuzumab + Trastuzumab + Chemotherapy	2,400
Overall Study	STARTED	Placebo + Trastuzumab + Chemotherapy	2,404
Overall Study	Received at Least 1 Dose of Pertuzumab	Pertuzumab + Trastuzumab + Chemotherapy	2,340
Overall Study	Received at Least 1 Dose of Pertuzumab	Placebo + Trastuzumab + Chemotherapy	24
Overall Study	Received Any Study Treatment Except for Pertuzumab	Pertuzumab + Trastuzumab + Chemotherapy	38
Overall Study	Received Any Study Treatment Except for Pertuzumab	Placebo + Trastuzumab + Chemotherapy	2,367
Overall Study	Entered Follow-Up	Pertuzumab + Trastuzumab + Chemotherapy	2,369
Overall Study	Entered Follow-Up	Placebo + Trastuzumab + Chemotherapy	2,381
Overall Study	COMPLETED	Pertuzumab + Trastuzumab + Chemotherapy	1,361
Overall Study	COMPLETED	Placebo + Trastuzumab + Chemotherapy	1,316
Overall Study	NOT COMPLETED	Pertuzumab + Trastuzumab + Chemotherapy	1,039
Overall Study	NOT COMPLETED	Placebo + Trastuzumab + Chemotherapy	1,088

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01358877/flow